You are here:
The study presents novel dihydroorotate dehydrogenase (DHODH) inhibitors with potent antimalarial activity, offering promising candidates for malaria chemoprevention.
The study identifies and characterises DNDI-6174, a promising preclinical drug candidate for treating visceral leishmaniasis.
CTx-648 is a selective KAT6A/KAT6B inhibitor that shows strong anti-tumor effects in ER-positive breast cancer.
